REG - N4 Pharma PLC - Attendance at the Company's annual general meeting

N4 PharmaAnnouncement

17/04/2020 07:00

RNS Number : 9238J
  
N4 Pharma PLC
  
17 April 2020
  
 

17 April 2020
 
N4 Pharma plc
("N4 Pharma", the "Company" or the "Group")
 
Attendance at the Company's annual general meeting
 
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, provides an update on the Company's annual general meeting ("AGM"), to be held at 10:00 a.m. on 23 April 2020.
 
Further to the Company's announcement on 25 March 2020, Shareholders are reminded that that only the formal business set out in the notice of meeting will be considered at the AGM and are discouraged from attending the AGM in person given the current Government advice.  Shareholders wishing to vote on any of the matters of business are instead urged to do so via completion of a proxy form which can be completed and submitted to the Company. Details of how to appoint a proxy are set out in the Company's Notice of AGM posted to Shareholders on 25 March 2020 and available on the Company's website, www.n4pharma.com.
 
As an alternative to attending the AGM, the Company is offering Shareholders the option of attending a presentation by Nigel Theobald, CEO, via videoconference at 2:30 p.m. on 23 April 2020. Shareholders wishing to join should contact Nigel Theobald at nigel@n4pharma.co.uk. No new information will be provided during the presentation.
 
Enquiries:
 




N4 Pharma Plc
Nigel Theobald, CEO
 


 
Via Scott PR




Allenby Capital Limited
James Reeve/Asha Chotai
 


Tel: +44(0)203 328 5656




Scott PR
Georgia Smith
 


Tel: +44(0)1477 539 539




 
About N4 Pharma
 
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
 
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
MSCSFDFDMESSESL